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ABSTRACT
Introduction. TNM status is questioned as an exact pre-
dictor of survival in different tumour entities. Recently,
lymph node ratio (LNR) has been described as a predictor
of survival in patients with HNSCC. The purpose of this
study was to evaluate to which degree LNR could be used
as a more accurate predictor than TNM staging?
Methods. A total of 291 patients, with a follow-up of at
least 3 years, were analyzed using log-rank statistic, uni-
variate and multivariate data analyzes, and p values, for
prediction of lymph node ratio on overall and recurrence-
free survival.
Results. Survival differed significantly if patients were
stratified for LNR. Impact of LNR on survival was sig-
nificantly different even in patients with extracapsular
spread. Patients with pN0 had no survival benefit compared
with patients with pN1 or higher with a LNR lower than
6 %.
Conclusions. LNR is a prognostic tool in patients with a
lymph node status pN0–pN2b. LNR remained significant
even in patients with extracapsular spread, contrary to
TNM status. With LNR, stratification for high-risk patients
(higher than 6 % LNR) can be evaluated easily. We would
suggest using LNR in the clinical routine.
BACKGROUND
The importance of lymph node status in head and neck
squamous cell carcinoma (HNSCC) is well documented
and has an important impact on recurrence-free (RFS) and
overall survival (OS). The presence of even one metastatic
lymph node reduces the outcome dramatically; however,
this poorer survival is not expressed when looking at the
prognostic value of the current TNM staging system. The
search for a prognostic significance within the TNM system
along with further prognostic factors is ongoing.1,2
With the introduction of lymph node ratio (LNR)—ratio
between number of affected lymph nodes and number of
excised lymph nodes—as a diagnostic tool in solid cancers,
such as gastric, endometrioid uterine, and colorectal can-
cer, interest has turned to the importance of nodal ratio in
oral cavity squamous cell carcinoma (OSSCC). Although
there is evidence for a prognostic value in oral cavity, other
regions in head and neck cancer were not investigated.3–5
In a recently published paper, LNR—besides extracapsular
spread—has been the only remaining independent prog-
nostic factor in HNSCC in a multivariate analysis.6
Although tumour staging according to the American
Joint Committee on Cancer (AJCC/UICC) is widely
accepted, therapy regimes based on these classifications
alone remain insufficient as the TNM system is based on
the simplistic concept of an orderly progression of the
tumour within surrounding tissues, then transgressing
lymphatic and vascular barriers. Evidence of a more
complex system is evolving leading to many other prog-
nostic parameters being investigated.1,2 Urban et al.7 have
demonstrated the importance of LNR to estimate the ben-
efit of postoperative radiotherapy in oral cavity cancer.
Conduction of Study Patient data derived from patients treated at
the University Hospital of Graz (1). The study was approved by the
Institutional Ethics Committee (EK-Nr. 21-020 ex 09/10).
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Association between LNR and lymph node staging does
currently not exist.
The study purpose is to address the following questions: is
LNR among patients with HNSCC, a more valid prognostic
factor for recurrence-free and overall survival than TNM
staging system; does this evidence valid for other regions than
the oral cavity in HNSCC; and to what extend is LNR a tool
for treatment decisions? Hypothesis of this study is that LNR,
if merged with tumour lymph node staging, offers a more
precise predictor for recurrence-free and overall survival, in
patients with HNSCC than mere nodal stage as a single factor.
To compare the relation between lymph node staging
and LNR, we looked at each aspect separately followed by
merging of the LNR and lymph node staging to evaluate
diversity between those two prognostic factors.
MATERIALS AND METHODS
Study Design
We developed a retrospective patient database for
patients who underwent primary surgery including neck
dissection for head and neck squamous cell carcinoma.
Study Sample
The study population was derived from patients who pre-
sented at the Department of Otorhinolaryngology and Head
and Neck (ENT) at the Medical University Hospital Graz for
treatment of HNSCC between 1 January 1999 and 31
December 2009. Of 465 patients, 291 met the criteria. The
study was approved by the institutional ethics committee.
Inclusion criteria were a diagnosis of HNSCC and opera-
tive treatment at the primary tumor site with or without
adjuvant radiotherapy or radiochemotherapy. Subjects were
excluded if they had histological findings other than SCC,
distant metastasis before neck dissection (ND), or were trea-
ted primarily outside the ENT department. Follow-up of
patients had to be documented for at least 3 years.
Patients were treated by resection of the primary tumour
combined with uni- or bilateral ND. Because this is a retro-
spective data collection, we cannot validate the indication of
the ND but can characterize them as radical, standardized
modified radical, or selective (supraomohyoidal, lateral,
posterolateral) as described by the American Head and Neck
Society.8 (Starting point of this study was before 2001,
therefore the Classification of 1991 was used.)
Study Variables
Variables examined were: age and sex; tumor location,
stage, size, and grade; neck lymph node status; histological
factors [vascular—(hemangiosis), lymphatic—(lymphang-
iosis), perineural invasion, extracapsular spread of lymph
nodes, conglomerate lymph nodes]; resection margin;
number of positive lymph nodes; LNR and use of adjuvant
therapy (postoperative chemotherapy and/or adjuvant
radiotherapy).
Points of Interest
Univariate analysis was used to identify factors signifi-
cantly affecting RFS and OS, and multivariate analyses of
significant factors was used to identify independent prog-
nostic factors.
Data Collection, Management, and Analyses
Data were collected and processed by building a data-
base of information about the patient (sex, age), tumour
(location, size, lymph node status), surgery (date, type of
resection, resection margin, type of ND, number of levels
excised, number of lymph nodes excised, number of
positive lymph nodes, excision of non lymphatic struc-
tures), histopathological diagnostic findings (hemangiosis,
lymphangiosis, extracapsular spread, perineural invasion),
postoperative therapy, second primary tumours, location
and time of recurrence, and OS. Patient data were analyzed
using SPSS software (SPSS Inc., Chicago, IL).
Descriptive statistics were computed for each variable.
Univariate Cox regression analysis was used for each
variable, and odds ratios and p values were calculated.
Multivariate Cox regression analysis was used for each
predictor variable (p \ 0.05) identified as significant in
univariate analysis. We used a forward step-wise (likeli-
hood ratio) procedure.
For the analysis of cutoff points for LNR, the ‘‘maxi-
mally selected rank statistic’’ method of Lausen and
Schumacher9 was used. Cutoff points with the highest
diversity of groups were calculated.
RESULTS
In total, 291 patients were included (Table 1). The mean
age was 64 (range, 27–87) years. Most (82.8 %) patients
were men. The mean follow-up duration was 38 months
(maximum, 128 months). Most patients had a tumour in
the oropharyngeal region (32 %), followed by the oral
cavity (25.4 %), hypopharynx (16.8 %), larynx (15.1 %),
unknown primary location (8.6 %), and nasopharynx
(2.1 %). Most patients presented with a stage IV tumour
(56 %), followed by stage III (19.6 %), stage II (13.7 %),
and stage I (10.7 %). Regarding T-status, most patients
presented with a T2 tumour (29.4 %). Lymph node status
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TABLE 1 Descriptive statistics of 291 patients
Attribute Number Percentage Mean SD Median Minimum Maximum
Age [in years] 291 64.08 10.6 64 27 87
Follow-up [mo] 291 38.39 32.6 27.2 0.1 128.3
Sex Male 241 82.8
Localization Oral cavity 74 25.4
Oropharynx 93 32
Nasopharynx 6 2.1
Hypopharynx 49 16.8
Larynx 44 15.1
Unknown primary 25 8.6
TNM stage Stage I–II 71 24.4
Stage III–IV 220 75.6
Tumor stage T1-2 150 51.6
T3-4 116 39.9
Tx 25 8.6
Lymph node status N0 109 37.5
N1 38 13.1
N2a 28 9.6
N2b 90 30.9
N2c 15 5.2
N3 11 3.8
Tumor grade Well/moderately differentiated 137 47
Poorly/undifferentiated 154 52.9
Perineural invasion No 268 92.1
Yes 23 7.9
Lymphangiosis No 270 92.8
Yes 21 7.2
Hemangiosis No 284 97.6
Yes 7 2.4
Capsule penetration No 237 81.4
Yes 54 18.6
Conglomerate lymph nodes No 261 89.7
Yes 30 10.3
Resection margin Negative 228 78.4
Positive 63 21.6
Number of positive lymph nodes 0 109 37.5
1 77 26.5
2–5 77 26.5
[5 28 9.6
Lymph node ratio 0–6 % 187 64.3
[6–13 % 48 16.5
[13 % 56 19.2
Lymph node ratio (pos/exc) [%] 291 8.04 13.0 3.7 0 100
Adjuvant therapy No 113 38.8
Radiotherapy 140 48.1
Chemotherapy 1 0.3
Radiochemotherapy 37 12.7
SD standard deviation
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was pN0 in 37.5 % of patients, followed by pN2b in nearly
31 % of patients. Because patients with distant metastasis
at diagnosis were excluded, all patients were in the M0
state.
Tumour grade was dominated by patients with moder-
ately (43.6 %) or poorly (51.2 %) differentiated tumours.
Only a few patients presented with well-differentiated or
undifferentiated tumours. Perineural invasion was seen in
7.9 % of patients; the percentage of lymphangiosis, he-
mangiosis, extracapsular spread, and conglomerate lymph
nodes was 7.2, 2.4, 18.6, and 10.3 %, respectively.
Operative success, defined as a negative resection mar-
gin by at least 5 mm (R0 resection), was achieved in
78.4 % of patients. R1 resection was achieved in 19.9 % of
patients and tumour resection was macroscopically positive
(R2 resection) in five (1.7 %) patients. Forty-one (14.1 %)
patients underwent radical ND. The largest proportion of
patients was treated with modified radical ND (28.9 %),
followed by supraomohyoidal (26.3 %), posterolateral
(25.1 %), and lateral selective (5.5 %) NDs.
In 66 patients, an additional selective contralateral neck
dissection of one level was conducted, if there were sus-
pected lymph nodes contralaterally. The mean number of
lymph nodes removed was 27 lymph nodes in total. Most
patients had a lymph node status higher than N1 (pN2) and
a lymph node density of 0–6 % (183 patients).
Results of neck dissections demonstrated a pN0 situa-
tion in 37.5 % of patients. One or 2–5 lymph nodes were
positive in 26.5 % in both groups. In 9.6 % of patients,
more than five lymph nodes were affected. Nearly two-
thirds of patients (187) had LNR between 0 and 6 %. A
LNR of [6-13 % was documented in 48 patients, and a
LNR higher than 13 % in 56 patients. In total, 113
(39.2 %) patients received no adjuvant therapy, 140
(48.1 %) patients received radiotherapy, 37 (12.7 %)
received combined radiochemotherapy, and 1 patient
received chemotherapy alone.
Two-thirds of patients (193) experienced no recurrence
during follow-up. Recurrence was observed in 98 (33.7 %)
cases; distant metastasis occurred in 34 % of these patients.
Both, RFS and OS differed significantly if patients were
stratified for LNR. Log-rank test was \0.001 for RFS
(Fig. 1) and OS (Fig. 1), each. RFS and OS remained sig-
nificant considering LNR if only patients with a pN2a and
pN2b were included in analysis (Fig. 2). LNR 0–6 % had a
significant favourable prognosis compared to LNR higher
than 6 % in those patients, with a p-value of 0.009 and
[0.001 for RFS and OS, respectively. Only seven patients
with a pN1 had a LNR of higher than 6 %; therefore,
comparison of RFS and OS in these patients could not be
sufficiently evaluated, and statistics were not valid.
If survival curve of patients with a negative neck were
compared to patients with a positive neck and a lymph
node ratio 0–6 %, there was no difference in run of curves.
Log-rank test was not significant at p = 0.561 (Fig. 3).
In patients with extracapsular spread, RFS was not
significant considering LNR. However, impact of lymph
node ratio on OS was significantly different even in
patients with extracapsular spread (p = 0.003) (Fig. 4).
There was no significant difference in RFS and OS of
patients without extracapsular spread after data was strat-
ified for TNM status.
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When the number of positive lymph nodes is considered as
sole factor, RFS and OS differed significantly if 0, 1, 2–5, or
more than five lymph nodes were affected. P value for RFS
and OS was 0.004 and \0.001, respectively. However, if
numbers of lymph nodes were stratified with lymph node
ratio, numbers of affected lymph nodes were not significant
any more.
Lymph node ratio remained a significant factor for RFS
and OS even if postoperative radiotherapy was applied
(p = 0.005 for each); however, no significance was
detected if radiochemotherapy was applied postoperatively
as adjuvant therapy.
DISCUSSION
It is advocated that the absence/presence of cervical
lymph node metastases is the most important prognostic
factor in HNSCC. The challenge is to evaluate accurately
the prognostic impact of positive cervical lymph nodes,
because N-classification does not predict tumour-free
survival.10
Among OSCC patients with positive neck nodes, Shing-
aki et al.11 proposed that nodal classification may not
necessarily predict prognosis. Descriptive TNM staging
cannot be used as survival predictive tool if not combined
with other descriptive prognostic factors, such as extracap-
sular spread, tumour infiltration, biomarkers to further
predict the biologic behaviour of an individual tumour, and
last but not least surgical success. In other tumour sites,
TNM status also is questioned as an exact predictor of sur-
vival. Lymph-node ratio (LNR) has been described as a
predictor of survival in patients with head and neck squa-
mous cell carcinoma. Furthermore, LNR is described to be
superior to TNM nodal status in patients with bladder can-
cer.12, 13 Ooki et al. 14 described the prognostic benefit of
LNR over TNM in advanced oesophageal squamous cell
carcinoma. In this article, lymph node ratio is evaluated
regarding its power for RFS and OS prediction.
Clayman et al.15 confounded lymph node levels at highest
risk for lymph node metastasis and set recommendations of
selective procedure for every tumour site in patients with
HNSCC. This hypothesis is supported by Patel et al.16 and
Shepard et al.17 who could not find a significant benefit of
comprehensive neck dissection versus selective neck dissection
for locoregional recurrence-free survival. With the knowledge
of lymph node levels most likely at risk for each tumour entity,
and the reassurance that a radical neck dissection is not superior
to selective procedures by the literature mentioned, LNR could
be a safety net along the way of selective lymph node surgery.
It is suggested that number of lymph nodes differ between
tumour patients and healthy people.18 Beasley et al.19 dem-
onstrated intratumoral lymphogenesis by using a lymphatic
endothelial marker, LYVE-1. Others described an increased
lymph vessel density in patients with oropharyngeal cancer.20
Hence, it is assumed that lymphatic tumour spread is sup-
ported by tumour-associated lymphogenesis and numbers of
excised lymph nodes during neck dissection may be of
importance to evaluate its potential for lymphogenesis and
may be a reflection of tumour biology characteristics.
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Patients with a single positive lymph node (pN1 or
pN2a) would benefit from lymph node ratio as a predictive
factor, for example in case of a diagnostic lymph node
dissection that happens to be one single positive lymph
node associated with an unfavourable LNR. According to
the LNR the patient may be offered an extension of his ND
to improve disease-specific survival. With the use of LNR,
underestimation of the neck situation might be prevented.
Patients with more than one positive ipsilateral lymph
node would benefit from LNR, because locoregional
tumour spread could be evaluated. For example, if two
lymph nodes are affected and a large number of excised
lymph nodes around those affected nodes are tumour-free
the possibility of metastasis to other areas is less likely,
similarly if metastasis of level 5 is present in absence of
involvement of levels 4 or 3.21 On the contrary, if a
comprehensive neck dissection delivers wide spread nodal
metastasis, distant metastasis is more likely to occur and
therefore additional treatment has to be considered.
Two situations should be mentioned where LNR cannot
be regarded as a diagnostic tool: (1) in case of lymph node
metastasis to the contralateral neck (pN2c); and (2) if one
or more lymph nodes are larger than 6 cm (N3) in diam-
eter. In case of pN2c, LNR is not valid, due to locoregional
tumour spread to the contralateral side; therefore, a bilat-
eral comprehensive neck dissection would be necessary to
use lymph node ratio for prediction. Likewise, in patients
with pN3, clear differentiation between one single lymph
node bigger than 6 cm or a conglomerate of smaller lymph
nodes often is not possible.
Importance of extracapsular tumour spread in patients
with HNSCC is well documented in the literature.22 Data
of this study could demonstrate the validity of LNR even in
patients with extracapsular spread. A ‘‘surrounding wall’’
or effective biologic barrier of not affected lymph nodes
seems to play a role in preventing distant metastasis.
According to the presented data—with the limitation of
a retrospective data analysis—LNR cannot only be used to
evaluate the effectiveness of the surgery, but also implicate
further therapies. Importance of LNR for decision making
towards adjuvant therapy seems to be a highly accurate
question that needs support by further prospective studies
on this issue. Unfavourable high lymph node ratio ([6 %)
should undergo further comprehensive surgery (if this was
not the case in first place) or be treated with adjuvant
therapy. The data presented demonstrated the unfavourable
prognosis of high lymph node ratio if solely radiotherapy
was applied. In combined postoperative treatment (radio-
chemotherapy), RFS and OS did not differ. However, the
indication that patients with higher LNR should be treated
with radiochemotherapy should be taken with precaution,
because the number of patients in this subgroup was only
37, thus limiting the statistical significance.
Some patients, especially in case of a pN2a status, might
be treated sufficiently by neck dissection only—with the
benefit of patient comfort, morbidity, and the chance of
radiotherapy in case of a recurrence—because of a benign
lymph node ratio.
In conclusion, is the hypothesis of whether LNR is
superior than TNM evaluated? In patients with a positive
lymph node status, but a lymph node ratio of 0–6 %, we
could demonstrate that RFS and OS did not differ comparing
to patients with a negative lymph node status. We could
demonstrate the significant difference in predicting RFS and
OS in patients with a pN2a and pN2b status after stratifying
lymph node ratio. Lymph node ratio remained significant in
patients with an extracapsular spread—contrary to TNM
status. Therefore, we suggest that LNR is used as a predictor
for survival in patients with an affected ipsilateral neck. If
contralateral neck is affected and/or lymph nodes are a
conglomerate, lymph node ratio is not valid.
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